Monday, November 11, 2024
9:54 AM EST – Medicenna Therapeutics Corp. : Presented updated clinical results from the ongoing monotherapy dose expansion and combination dose escalation portions of the Phase 1/2 ABILITY-1 (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, as monotherapy or in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Houston, Texas, on November 9. Medicenna Therapeutics Corp. (T.MDNA) shares were down $0.01 at 2.16.
Stocks in Play: Medicenna Therapeutics Corp. , Mon, 11 Nov 2024 09:57:06 EST